HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis |
Type de publication | Journal Article |
Year of Publication | 2018 |
Auteurs | Sevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JLuc, Lacout C, Cordonnier M, Rodrigues-Lima F, Chanteloup G, Mosca M, Chretien M-L, Bastie JNoel, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, Plo I, Garrido C, Girodon F, de Thonel A |
Journal | NATURE COMMUNICATIONS |
Volume | 9 |
Pagination | 1431 |
Date Published | APR 12 |
Type of Article | Article |
ISSN | 2041-1723 |
Résumé | Heat shock protein 27 (HSP27/HSPB1) is a stress-inducible chaperone that facilitates cancer development by its proliferative and anti-apoptotic functions. The OGX-427 antisense oligonucleotide against HSP27 has been reported to be beneficial against idiopathic pulmonary fibrosis. Here we show that OGX-427 is effective in two murine models of thrombopoietin- and JAKV617F-induced myelofibrosis. OGX-427 limits disease progression and is associated with a reduction in spleen weight, in megakaryocyte expansion and, for the JAKV617F model, in fibrosis. HSP27 regulates the proliferation of JAK2V617F-positive cells and interacts directly with JAK2/STAT5. We also show that its expression is increased in both CD34(+) circulating progenitors and in the serum of patients with JAK2-dependent myeloproliferative neoplasms with fibrosis. Our data suggest that HSP27 plays a key role in the pathophysiology of myelofibrosis and represents a new potential therapeutic target for patients with myeloproliferative neoplasms. |
DOI | 10.1038/s41467-018-03627-9 |